Theradaptive has treated the first patient in its clinical study evaluating OsteoAdapt DE, a product designed to generate bone growth following alveolar ridge augmentation surgery.
The randomized, controlled, and blinded study will evaluate the product’s safety and performance of OsteoAdapt DE in alveolar ridge augmentation. OsteoAdapt DE uses AMP2, the company’s variant of recombinant human bone morphogenetic protein-2, to recruit stem cells and drive controlled bone regeneration, Theradaptive said in a news release. The goal is to speed healing, improve surgical outcomes, and prepare patients for implants faster, according to the company.
